Company intelligence / Profile preview

Coherent Medicines

Ownership: Private
Employees: ~110
Development stage: Preclinical

Overview

CBP‑1008 shows encouraging efficacy and favorable safety profile in ovarian cancer patients. CBP‑1018 demonstrated superior profile with median progression-free survival of ~7 months for third-line mCRPC patients. Next-gen candidate CBP‑1019 shows improved safety and efficacy compared to antibody-drug conjugates using TOP1 inhibitors[4].

Therapeutic areas: Oncology
Modalities: Bispecific ligand drug conjugates (Bi-XDC technology platform)PROTACs (Proteolysis Targeting Chimeras)Radiopharmaceutical Therapy (RPT)
Industry: Biotech

Beyond the preview

Go deeper on Coherent Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coherent Medicines.

Explore the full profile